GlaxoSmithKline PLC (NYSE:GSK) announced its quarterly earnings data on Wednesday. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02, Morningstar.com reports. The business had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%.
Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.24% during trading on Thursday, reaching $40.75. 3,673,080 shares of the company traded hands. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58. The company has a market capitalization of $99.55 billion, a price-to-earnings ratio of 45.58 and a beta of 1.04. The firm’s 50 day moving average price is $42.93 and its 200-day moving average price is $41.77.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a dividend yield of 4.82%. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is currently 233.74%.
Several analysts have issued reports on the stock. Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. ValuEngine downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday. Finally, BNP Paribas raised shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $45.58 to $37.20 in a research note on Wednesday, April 5th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $46.00.
Institutional investors have recently modified their holdings of the company. Carroll Financial Associates Inc. increased its stake in shares of GlaxoSmithKline PLC by 0.4% in the second quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock valued at $374,000 after buying an additional 35 shares in the last quarter. First National Bank of Omaha increased its stake in shares of GlaxoSmithKline PLC by 0.3% in the second quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after buying an additional 57 shares in the last quarter. Pekin Singer Strauss Asset Management IL increased its stake in shares of GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares in the last quarter. Baystate Wealth Management LLC increased its stake in shares of GlaxoSmithKline PLC by 1.4% in the second quarter. Baystate Wealth Management LLC now owns 5,520 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 75 shares in the last quarter. Finally, Investment Partners Ltd. OH ADV increased its stake in shares of GlaxoSmithKline PLC by 0.8% in the second quarter. Investment Partners Ltd. OH ADV now owns 9,491 shares of the pharmaceutical company’s stock valued at $409,000 after buying an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 8.98% of the company’s stock.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
